SCHEMBL448424

SCHEMBL448424

Cc1ccc(-n2c(C(C)N(C)S(=O)(=O)c3ccc(-c4ccccc4)cc3)nc3ccccc3c2=O)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.53
MAPT P10636 3/20 0.50
KDM4E B2RXH2 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDO2 P48775 1/20 0.45
IDO2 Q6ZQW0 1/20 0.45
LMNA P02545 3/20 0.40
GLA P06280 1/20 0.40
CXCR3 P49682 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
C1R P00736 1/20 0.39
PRSS1 P07477 1/20 0.39
GAA P10253 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ADAMTS4 O75173 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL454036 0.95 ALDH1A1 (0.56) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2
SCHEMBL449258 0.92 ALDH1A1 (0.53) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2
SCHEMBL451269 0.90 ALDH1A1 (0.51) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2
SCHEMBL452757 0.90 ALDH1A1 (0.51) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2
SCHEMBL454513 0.90 ALDH1A1 (0.53) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2
SCHEMBL451983 0.90 ALDH1A1 (0.54) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2
SCHEMBL453295 0.89 ALDH1A1 (0.50) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2
SCHEMBL449870 0.89 ALDH1A1 (0.50) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2
SCHEMBL451866 0.89 ALDH1A1 (0.50) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2
SCHEMBL449873 0.88 ALDH1A1 (0.51) ALDH1A1MAPTKDM4ESMN1; SMN2TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US claimed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP claimed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885MAPT 4075/4885KDM4E 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.